# CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

> **NCT06690775** · PHASE2 · RECRUITING · sponsor: **TORL Biotherapeutics, LLC** · enrollment: 230 (estimated)

## Conditions studied

- Epithelial Ovarian Cancer
- Primary Peritoneal
- Fallopian Tube Cancer
- Endometrioid Ovarian Cancer

## Interventions

- **DRUG:** TORL-1-23
- **DRUG:** TORL-1-23
- **DRUG:** TORL-1-23
- **DRUG:** Pegfilgrastim (drug)

## Key facts

- **NCT ID:** NCT06690775
- **Lead sponsor:** TORL Biotherapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-20
- **Primary completion:** 2027-10
- **Final completion:** 2027-12
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2025-12-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06690775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06690775, "CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT06690775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*